

Fresenius Kabi Canada Ltd.

165 Galaxy Blvd, Suite 100 Toronto, Ontario Canada M9W 0C8 T: 905.770.3711

F: 844.513.1522 W: fresenius-kabi.ca

June 2, 2022

Mannitol Injection Allocation Notice

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that due to a production delay, our **Mannitol Injection 250 mg/mL SD Vial 50 mL** will be placed on allocation effective **June 2, 2022**. Contract customers will be allocated **100% of historical monthly demand**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Supply Status
02243176	C1550	922511	482232	Mannitol Injection 250 mg/mL SD Vial 50 mL	On 100% Allocation effective Jun. 2, 2022

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

George Shamsoun

Associate Director – Marketing, IV Drugs george.shamsoun@fresenius-kabi.com